Home Disclaimer

Disclaimer

Disclaimer and Terms of Use

Copyright © 2011-Present JournalTranscript.com, All Rights Reserved. 

JournalTranscript d/b/a www.JournalTranscript.com (“Site,” “JournalTranscript,” “us,” “our” or “we”) is an affiliate of JournalTranscript.com Networks is owned and operated by EDM LLC, provides this website to you under the following terms and conditions (“Terms of Use”).

BY CONTINUING TO USE THE SITE, YOU ARE INDICATING YOUR AGREEMENT TO BE BOUND BY THIS DISCLAIMER, OUR TERMS OF USE AND OUR PRIVACY POLICY IN EFFECT AT SUCH TIME AND ALL OTHER OPERATING RULES, POLICIES AND PROCEDURES THAT MAY BE PUBLISHED BY US FROM TIME TO TIME ON THE SITE, EACH OF WHICH IS INCORPORATED BY REFERENCE AND EACH OF WHICH MAY BE UPDATED BY US FROM TIME TO TIME WITHOUT NOTICE TO YOU.  

General Guidelines

JournalTranscript grants you a limited, revocable, non-exclusive, non-transferrable license to view content on the Site for personal and non-commercial purposes. JournalTranscript grants the operators of public search engines a limited, non-exclusive, non-transferrable license to copy materials from the Site for the purpose of creating publicly available, searchable indices of Site content. You agree not to modify, damage, disrupt, disable, overburden, impair, alter or interfere with the use, features, functions, operation, security or maintenance of the Site or the rights or use and enjoyment of the Site by any other person or entity in any manner. No portion of JournalTranscript.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law.

Paid Advertisement and Sponsored Content

The Content provided on this Site is our own original content or is paid advertisements provided exclusively by our affiliate, JournalTranscript.com Networks, an financial media and news marketing firm. JournalTranscript.com Networks has entered into service agreements with the companies which are the subject to the articles posted on the Site for promoting such companies.  The companies mentioned on the Site may or may not have not approved the content or timing of the information being published unless otherwise noted.  We are not a financial advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. You understand and acknowledge that there is a very high degree of risk involved in trading securities mentioned on JournalTranscript. JournalTranscript, the authors, the publisher, and all affiliates of JournalTranscript (including their respective directors, officers and employees) assume no responsibility or liability for your trading and investment results.

Compensation Arrangements

JournalTranscript receives fees for producing and presenting the Content on this Site along with other media services.  Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this Site, or a combination thereof.  The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement.  We note that this pay structure creates a pecuniary interest in increasing the stock price, which we may benefit from.

METHODS OF DISSEMINATION

The Publisher may use various types of media (the “Media”) to disseminate the Information, at its discretion without notice to Recipients. The Information may be published on and/or through any or all the non-exclusive methods below:

  • Ticker Tags (as defined under heading “DISCLAIMERS AND RISKS”
  • websites owned, controlled and/or operated by the Publisher
  • websites owned and/or operated by the Publisher’s affiliates and non-affiliates,
  • online communities, financial forums, trader and investor chat rooms, social media platforms and/or newsletters using online identities some or all of which may or may not be anonymous,
  • text message alerts,
  • audio services,
  • online live interviews,
  • news outlets located, coordinated or paid by the Publisher,
  • email communications, and
  • other communications sent to the Recipients from time to time.

For IR/PR services, please contact steve@edm.media

This website is run by EDM Media aka EDM LLC. JournalTranscript is not responsible for any content posted by EDM Media LLC. We have not verified any of the content posted on our website by EDM Media and his associate Brett Manning and are merely providing a platform to post the content.

For IR/PR services or any questions on pertaining to content posted on WallStreetPR.com, JournalTranscript.com and BiopharmaJournal.com, please contact steve@edm.media

WallStreetPR and its sister websites Biopharmajournal.com, JournalTranscript.com expects to be compensated for letting EDM Media post on our website for content related to AXXA, CSOC and KULR from May 15th to May 23rd, 2021. We have not verified any of the content posted on our website by EDM Media and its associates and are merely providing a platform to share the content.

WallStreetPR and its sister websites Biopharmajournal.com, JournalTranscript.com have been compensated a total of 8000$ for letting EDM Media post on our website for content related to RLBD and HWAL from May 15th to May 23rd, 2021. We have not verified any of the content posted on our website by EDM Media and its associates and are merely providing a platform to share the content.

WallStreetPR and its sister websites Biopharmajournal.com, JournalTranscript.com have been compensated a total of 2000$ for letting EDM Media post on our website for content related to MJWL, MEDH, AXXA, CSOC, and KULR from May 10th to May 17th, 2021. We have not verified any of the content posted on our website by EDM Media and its associates and are merely providing a platform to share the content.

WallStreetPR and its sister websites Biopharmajournal.com, JournalTranscript.com have been compensated a total of 1300$ for letting EDM Media post on our website for content related to AGYP, KULR and EPAZ from May 3rd to May 9th, 2021. We have not verified any of the content posted on our website by EDM Media and its associates and are merely providing a platform to share the content.

JournalTranscript.com has been compensated 2578$ for letting EDM Media post on our website for content related to KULR, SFLM, TQLB, AXXA, CSOC, MEDH, AGYP, INKW, RLBD from April 12th to 16th, 2021.

JournalTranscript.com has been compensated 2200$ for a content marketing program on CBDL
MEDH, AXXA, CSOC, SFLM, BNOW, RLBD, KULR, SPYR, BTIM for April 5th to 9th, 2021.

JournalTranscript.com has been compensated 2400$ for a content marketing program on KULR. SPYR. CSOC. BTIM. AXXA. SGMD for the 4th week of March, 2021.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on ALST starting 10/01/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on TOMI starting 10/01/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on SCNG starting 10/01/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on ALST starting 09/28/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on TOMI starting 09/28/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on RXMD starting 09/28/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on SCNG starting 09/28/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on SCNG starting 09/21/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on TOMI starting 09/21/2020

JournalTranscript.com has been compensated $250 for a  publishing a ticker tag article on EGMCF on 10/07/2020.

JournalTranscript.com has been compensated $5,500 for a content marketing campaign on SCNG starting 09/14/2020.

JournalTranscript.com has been compensated $5,500 for a content marketing campaign on TONJ starting 09/14/2020.

JournalTranscript.com has been compensated $7,000 for a content marketing campaign on ALST starting 09/14/2020.

JournalTranscript.com has been compensated $5,000 for a content marketing campaign on TONJ starting 08/10/2020.

JournalTranscript.com has been compensation $5,000 for a content marketing campaign on AFFU starting 07/20/2020.

JournalTranscript.com has been compensation $5,000 for a content marketing campaign on KULR starting 07/16/2020.

JournalTranscript.com has been compensation $400 for a content marketing campaign on ECOX starting 07/13/2020.

JournalTranscript.com has been compensation $400 for a content marketing campaign on CLKA starting 07/13/2020.

JournalTranscript.com has been compensation $400 for a content marketing campaign on MCTC starting 07/13/2020.

JournalTranscript.com has been compensation $400 for a content marketing campaign on SGMD starting 07/13/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on RXMD starting 07/13/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on HRAL starting 07/13/2020.

JournalTranscript.com has been compensation $4,000 for a content marketing campaign on PSRU starting 07/13/2020.

JournalTranscript.com has been compensation $5,000 for a content marketing campaign on AEPT starting 07/13/2020.

JournalTranscript.com has been compensation $2,000 for a content marketing campaign on GTEH starting 07/08/2020.

JournalTranscript.com has been compensation $4,500 for a content marketing campaign on SURG starting 07/07/2020.

JournalTranscript.com has been compensation $2,500 for a content marketing campaign on ALST starting 07/06/2020.

JournalTranscript.com has been compensation $6,500 for a content marketing campaign on BTHR starting 07/06/2020.

JournalTranscript.com has been compensation $4,500 for a content marketing campaign on HRAL starting 07/06/2020.

JournalTranscript.com has been compensation $4,500 for a content marketing campaign on FUSEF starting 06/22/2020.

JournalTranscript.com has been compensation $5,500 for a content marketing campaign on RXMD starting 06/22/2020.

JournalTranscript.com has been compensation $5,000 for a content marketing campaign on ALST starting 06/22/2020.

JournalTranscript.com has been compensation $2,500 for a content marketing campaign on HRAL starting 06/08/2020.

JournalTranscript.com has been compensation $3,000 for a content marketing campaign on HRAL starting 06/15/2020.

JournalTranscript.com has been compensation $7,500 for a content marketing campaign on BLGO starting 05/18/2020.

JournalTranscript.com has been compensation $4000 for a content marketing campaign on CLOQ starting 05/08/2020.

JournalTranscript.com has been compensation $5000 for a content marketing campaign on GCGX starting 05/07/2020.

JournalTranscript.com has been compensation $10,000 for a content marketing campaign on PLIN starting 04/29/2020.

JournalTranscript.com has been compensation $10,000 for a content marketing campaign on QBIO starting 04/29/2020.

JournalTranscript.com has been compensated $4500 for a content marketing campaign for one week on TMBXF starting 04/15/2020.

JournalTranscript.com has been compensated $5000 for a content marketing campaign on RXMD starting 04/02/2020.

JournalTranscript.com has been compensated $1250 for a content marketing campaign on HMPQ starting 04/01/2020.

JournalTranscript.com has been compensated $5000 for a content marketing campaign on RXMD starting 03/23/2020.

JournalTranscript.com has been compensation $5000 for a content marketing campaign on ISWH starting 03/30/2020.

JournalTranscript.com has been compensation $4000 for a content marketing campaign on ISWH starting 03/23/2020.

JournalTranscript.com has been compensation $5000 for a content marketing campaign on RXMD starting 03/18/2020.

JournalTranscript.com has been compensation $2000 for a content marketing campaign on SURG starting 03/17/2020.

JournalTranscript.com has been compensation $3500 for a content marketing campaign on IPIX starting 03/06/2020.

JournalTranscript.com has been compensation $5500 for a content marketing campaign on SDEC starting 03/06/2020.

JournalTranscript.com has been compensation $3500 for a content marketing campaign on SURG starting 02/19/2020.

JournalTranscript.com has been compensation $3500 for a content marketing campaign on SKDI starting 02/24/2020.

JournalTranscript.com has been compensation $9750 for a content marketing campaign on NGTF starting 02/18/2020.

JournalTranscript.com has been compensation $2500 for a content marketing campaign on SKDI starting 02/17/2020.

JournalTranscript.com has been compensation $7500 for a content marketing campaign on RXMD starting 01/28/2020.

JournalTranscript.com has been compensation $8500 for a 5-day content marketing campaign on SURG starting 01/27/2020.

JournalTranscript.com has been compensation $2500 for a content marketing campaign on SDEC starting 01/20/2020.

JournalTranscript.com has been compensation $5000 for a content marketing campaign on GDET starting 01/20/2020.

JournalTranscript.com has been compensation $5000 for a content marketing campaign on TMGI starting 01/20/2020.

JournalTranscript.com has been compensation $5500 for a 5-day content marketing campaign on SURG starting 01/20/2020.

JournalTranscript.com has been compensation $5000 for a content marketing campaign on NUGS starting 01/20/2020.

JournalTranscript.com has been compensation $8500 for a 5-day content marketing campaign on SURG starting 01/08/2020.

JournalTranscript.com has been compensation $7500 for a 5-day content marketing campaign on RXMD starting 01/13/2020.

JournalTranscript.com has been compensation $6500 for a 5-day content marketing campaign on ERBB starting 01/08/2020.

JournalTranscript.com has been compensation $5500 for a 5-day content marketing campaign on SURG starting 01/13/2020.

JournalTranscript.com has been compensation $1000 for a content marketing campaign on SGMD starting 12/20/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on GDET starting 12/16/2019.

JournalTranscript.com has been compensation $2000 for a content marketing campaign on SDEC starting 12/09/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on IMTL starting 12/06/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on RXMD starting 12/05/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on GDET starting 11/27/2019.

JournalTranscript.com has been compensation $1250 for a content marketing campaign on RXMD starting 11/27/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on RXMD starting 11/20/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on RXMD starting 11/13/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on SKDI by Elliot Harris starting 11/11/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on RXMD starting 11/05/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on SKDI by Elliot Harris starting 11/04/2019.

JournalTranscript.com has been compensation $5500 for a 10-day content marketing campaign on IMTL by Beacon Capital LLC. starting 11/04/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on GDET by Beacon Capital LLC. starting 11/04/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on IMTL by Beacon Capital LLC. starting 10/28/2019.

JournalTranscript.com has been compensation $5500 for a 10-day content marketing campaign on GDET by Beacon Capital LLC. starting 10/28/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on IMTL by Beacon Capital LLC. starting 10/21/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on GDET by Beacon Capital LLC. starting 10/21/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on GDET by Beacon Capital LLC. starting 10/14/2019.

JournalTranscript.com has been compensation $5500 for a 10-day content marketing campaign on IMTL by the company itself starting 10/07/2019.

JournalTranscript.com has been compensation $500 for a 1- article post on HMPQ by the company itself starting 10/02/2019.

JournalTranscript.com and its associated sites have been compensated $2,500.00 in Cash for the month of October, 2019 (30 days)  from Cream Consulting LLC for 30 day advertisement services on MDCL.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on IMTL by the company itself starting 09/30/2019.

JournalTranscript.com has been compensation $3500 for a 3-day content marketing campaign on HLYK by the company itself starting 09/30/2019.

JournalTranscript.com has been compensation $6500 for a 3-day content marketing campaign on EDNT by third party World Wide Holdings LLC starting 09/25/2019.

JournalTranscript.com has been compensation $5000 for a 5-day content marketing campaign on IMTL by the company itself starting 09/23/2019.

JournalTranscript.com has been compensation $6500 for a 3-day content marketing campaign on EDNT by third party World Wide Holdings LLC starting 09/19/2019.

JournalTranscript.com and its associated sites have been compensated $3,500.00 on Sep 9th, 2019 from the company to Cream Consulting LLC for 3 days advertisement services on UCLE.

JournalTranscript.com and its associated sites have been compensated $2,500.00 in Cash for the month of Sep, 2019 (30 days)  from Cream Consulting LLC for 30 day advertisement services on MDCL.

JournalTranscript.com has been compensated $5000.00 from Think Ink Marketing for advertisement services on KERMF for the month of September, 2017.

JournalTranscript.com has been compensated $7,500.00 from Think Ink Marketing for advertisement services on STLHF for the month of July, 2017.

JournalTranscript.com has been compensated $3,000.00 from Cream Consulting LLC for 2 weeks of advertisement services on SHIP starting 19th June to 3rd July 2017.

JournalTranscript.com has been compensated $5,000.00 in Cash on June 1st, 2017 from Cream Consulting LLC for 1 month advertisement services on OBMP.

JournalTranscript.com has been compensated $5,000.00 by Cream Consulting LLC for 1 month advertisement services on SING for the month of May, 2017.

JournalTranscript.com has been compensated $2,000.00 in Cash on March 1st, 2017 from Cream Consulting LLC for 1 month advertisement services on OBMP.

JournalTranscript.com has been compensated $2,000.00 in Cash on March 1st, 2017 from Cream Consulting LLC for 1 month advertisement services on CMXC.

JournalTranscript.com has been compensated $2,000.00 in Cash on Feb 1st, 2017 from Cream Consulting LLC for 1 month advertisement services on VRSSF.

JournalTranscript.com has been compensated $2,000.00 in Cash on Jan 01, 2017 from Cream Consulting LLC for 1 month advertisement services on SPYR.

JournalTranscript.com has been compensated $2,000.00 in Cash on Jan 01, 2017 from Cream Consulting LLC for 1 month advertisement services on OBMP.

JournalTranscript.com has been compensated $2,000.00 in Cash on Dec 1, 2017 from Cream Consulting LLC for 1 month advertisement services on BFGC.

No Securities or Investment Advice or Recommendations

JournalTranscript.com is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. None of the Content on the Site shall constitute a recommendation to buy, sell, or hold that or any other security, financial product or investment discussed herein.  As with any investment, the featured companies on the Site or in any communication to you involves a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any financial instrument and/or security.  Neither the U.S. Securities and Exchange Commission nor any state securities administrator has reviewed or approved the information presented on this Site or passed upon the merits, accuracy or completeness of any of the Content.  JournalTranscript, its affiliates, employees, directors and agents make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the featured companies and does not guarantee the topicality, correctness, completeness and quality of information and statements presented on the Site or in any email alerts, newsletters or other such communications. You are strongly advised to and agree to consult a financial advisor and to independently diligence any contemplated investment.

You further understand and hereby agree that the Site does not offer or provide any investment advice or opinion regarding the nature, potential, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. You hereby agree that any investment decisions you make will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, financial condition, and liquidity needs. You acknowledge, understand and agree that small and micro-cap stocks are high-risk investments and that you may lose the entirety of your investment, and further that JournalTranscript shall not be responsible or liable for any trading or investment decisions made based on such information.

Cautionary Note Regarding Forward-Looking Statements

The Content published on the Site may include “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act or similar applicable regulation. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology.  Such forward-looking statements which are subject to known and unknown risks, uncertainties and assumptions about us, may include, but are not limited to, projections of financial performance based on growth strategies and anticipated trends, statements concerning issuer’s plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are only predictions based current expectations about future events. They involve risks and uncertainties that could cause actual results, level of activity, performance or achievements to differ materially from those expressed or implied in such forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any forward-looking statements after the date of publication to conform our prior statements to actual results or revised expectations and we do not intend to do so.

Resources

Investing in emerging growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We encourage our readers to invest carefully and read the investor information available at the websites of the Securities and Exchange Commission (“SEC”) at www.sec.gov and/or the Financial Industry Regulatory Authority (“FINRA”) at www.finra.org. Investing in emerging growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We encourage our readers to invest carefully and read the investor information available at the websites of the Securities and Exchange Commission (“SEC”) at www.sec.gov and/or the Financial Industry Regulatory Authority (“FINRA”) at www.finra.org.

Third-Party Companies & Products

Mention of third-party products, companies and web sites on the JournalTranscript.com Site is for informational purposes only and constitutes neither an endorsement nor a recommendation. JournalTranscript.com assumes no responsibility with regard to the selection, performance or use of these products or vendors. JournalTranscript.com provides this only as a convenience to our users. JournalTranscript.com has not tested any software found on these web sites and makes no representations regarding the quality, safety, or suitability of any software found there. There are dangers inherent in the use of any software found on the Internet, and JournalTranscript.com assumes no responsibility with regard to the performance of use of these products. Make sure that you completely understand the risks before retrieving any software on the Internet. All third party products must be ordered directly from the vendor, and all licenses and warranties, if any, take place between you and the vendor.

Intellectual Property

JournalTranscript.com authorizes you to view and download the Content on this Site only for your personal, non-commercial use, provided that you retain all copyright and other proprietary notices contained in the original Content on any copies of the Content. You may not modify the Content of this Site in any way or reproduce or publicly display, perform, or distribute or otherwise use it for any public or commercial purpose. Any use of the Content on any other web site or networked computer environment for any purpose is prohibited. The trademarks, logo and slogans displayed on the Site, including but not limited to the “JournalTranscript”, our newsletter and/or and other communication to you (collectively the “Trademarks”) are owned by JournalTranscript and others. Nothing on this Site or any other communication to you should be construed as granting any license or right to use the Trademarks without express prior written permission of JournalTranscript. Your misuse of the Trademarks, or any other Content on the Site, except as provided in these Terms of Use, is strictly prohibited. You are advised that JournalTranscript will aggressively enforce its intellectual property rights to the fullest extent of the law. All software and content included on this site, such as text, graphics, logos, button icons, images, audio clips, and software, is the owned or licensed property of JournalTranscript or its software and content suppliers and protected by U.S. and international copyright laws. The compilation (meaning the collection, arrangement, and assembly) of all content on this Site is the exclusive property of JournalTranscript and protected by U.S. and international copyright laws. JournalTranscript grants you permission to view and use content and software made available to you on the site in connection with your use of the site. Any other use, including the reproduction, modification, distribution, transmission, republication, display, or performance, of the content and software on this site is strictly prohibited. If you use the materials or Trademarks on this Site in a way that is not clearly allowed by these Terms of Use, you are violating your agreement with us and may be violating copyright, trademark, and other laws. In that case, we automatically revoke your permission to use this Site. Title to the materials remains with us or with the authors of the materials contained on this website. All rights not expressly granted are reserved.

No Representations or Warranties

JournalTranscript does not represent or warrant the reliability or accuracy of any Content distributed through or accessed from the Site, and has not performed any investigation into such Content.  To the fullest extent permissible by law, JournalTranscript assumes no liability or responsibility for any errors or omissions in the Content provided on this the Site. JournalTranscript.com provides the information and data presented on this Site “AS IS”. JournalTranscript.com expressly disclaims all warranties and/or conditions, express or implied, as to any matter whatsoever relating to or referenced by this Site, including, but not limited to, the implied warranties and/or conditions of merchantability or satisfactory quality and fitness for a particular purpose and non-infringement, or arising from a course of dealing, usage, trade or practice. JournalTranscript.com shall not be liable for any technical inaccuracies or typographical errors, which this Site may contain. In no event will JournalTranscript.com be liable to any party for any direct, special or other consequential damages for any use of this Site, or any other web site, including without limitation, any lost profits, business interruption, loss of programs or other data, even if JournalTranscript.com is advised of the possibility of such damages.

JournalTranscript.com makes no representations whatsoever about any other web site which you may access through this Site. These web sites are independent from JournalTranscript.com and we have no control over the content of other companies’ web sites. It is the User’s responsibility, not JournalTranscript.com to take precautions to ensure the linked web sites are free of viruses or other items of a potentially damaging nature. The information contained in this Site is subject to change without notice.

Indemnity

 You hereby expressly agree to indemnify, defend and hold JournalTranscript.com and all of its owners, agents, employees, directors, licensors and licensees (collectively, “Indemnified Parties”) harmless from and against any and all liability and costs, including, without limitation, attorneys’ fees and costs, incurred by the Indemnified Parties in connection with any claim arising out of any breach by you of these Terms of Use, or any of the representations, warranties, disclaimers and covenants contained herein. JournalTranscript.com reserves the right, at its own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification by you and you shall not in any event settle any matter without the written consent of JournalTranscript.com.

Applicable Laws

This Site is administered by JournalTranscript.com or authorized developers of JournalTranscript.com from their offices around the world. JournalTranscript.com makes no representation that Materials at this Site are appropriate or available for use outside the United States, and access to them from territories where their contents are illegal is prohibited. You may not use or export or re-export the Materials at this Site or any copy or adaptation in violation of any applicable laws or regulations including without limitation U.S. export laws and regulations. If you choose to access this Site from outside the United States, you do so on your own initiative and are responsible for compliance with applicable local laws. These terms and conditions will be governed by and construed in accordance with the laws of the State of Nevada, without giving effect to any principles of conflicts of laws.

US Jurisdiction

The Content provided on this site is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation. If you are located outside of the United States, your use of the Site is done on your own risk and initiative and you, not us, are responsible for compliance with any applicable local and national laws. The content, material and information contained on the Site does not constitute an offer or solicitation and may not be treated as an offer or solicitation (i) in any jurisdiction where such an offer or solicitation is against the law; (ii) to anyone to whom it is unlawful to make such an offer or solicitation: (iii) if the person making the offer or solicitation is not qualified to do so.

This Site is not directed at you if we are prohibited by any law of any jurisdiction from making the information on this site available to you. You should satisfy yourself before accessing the Site that we would be allowed to provide the Content to you under the law of the jurisdiction in which you reside. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction, including the one in which you reside.

Privacy Statement

JournalTranscript.com respects the privacy of users of this Site and believes that such information should be used responsibly and appropriately. In general, all users may visit this Site anonymously and without revealing any personal information. We may keep track of visitors’ IP addresses, the browser used and other related data. We analyze this data for trends and statistics. We may also collect information automatically provided to us by your browser about the type of computer and operating system you are using. This privacy statement does not extend to anything that is beyond the control of JournalTranscript.com, and is not to be applied in any manner contrary to applicable policies, laws, rules or regulations. Any communication or material you transmit to JournalTranscript.com via this Site, via electronic mail or otherwise, including any data, comments, questions, etc., will be treated as non-confidential and non-proprietary.

Waiver of Rights

The failure of JournalTranscript to enforce any right or provision of these Terms of Use will not constitute a waiver of future enforcement of that right or provision. The waiver of any such right or provision will be effective only if in writing and signed by a duly authorized representative of JournalTranscript. Except as expressly set forth in these Terms of Use, the exercise by either party of any of its remedies under these Terms of Use will be without prejudice to its other remedies under these Terms of Use or otherwise. If for any reason a court or arbitral, as applicable, of competent jurisdiction finds any provision of these Terms of Use invalid or unenforceable, that provision will be enforced to the maximum extent permissible and the other provisions of these Terms of Use will remain in full force and effect.

Miscellaneous

Except as expressly provided in these Terms of Use, there shall be no third-party beneficiaries to the Terms of Use. Journal Transcript  shall have the right to assign its rights or delegate any of its responsibilities under these Terms of Use to an affiliate or in connection with a merger, consolidation or reorganization of JournalTranscript for the sale of substantially all of its assets. In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the parties hereto. You further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision. You represent, warrant and covenant that: (i) you have the power and authority to enter into this agreement; and (ii) you are at least eighteen (18) years old.

These Terms of Use contain the entire understanding between you and JournalTranscript relating to the Site and JournalTranscript’s services. These Terms of Use supersede any other Terms of Use or agreement regarding the Site and JournalTranscript’s services prior to the date hereof. Full disclosure can be found in accordance with section 17(b) of the Securities Act of 1933 for every publication and at full disclaimer page.